Immune hemolytic anemia associated with drug therapy

Blood Reviews

Volumn 24, Issue 4-5, 2010, Pages 143-150

  Garratty, George ^a  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

Author keywords

Cephalosporins and hemolytic anemia; Drug antibodies; Drugs and hemolytic anemia; Fludarabine and hemolytic anemia; Hemolytic anemia; Piperacillin and hemolytic anemia

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BETA LACTAMASE INHIBITOR; CEFOTETAN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DRUG ANTIBODY; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MEMBRANE PROTEIN; METHYLDOPA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINIDINE; QUININE; RITUXIMAB; STEROID; TACROLIMUS;

ADSORPTION; ANTIBIOTIC PROPHYLAXIS; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD TRANSFUSION REACTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COVALENT BOND; DRUG DOSE INCREASE; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE APLASIA; ERYTHROCYTE MEMBRANE; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVASCULAR HEMOLYSIS; LIVER TRANSPLANTATION; MEMBRANE BINDING; PANCREAS TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTI-INFECTIVE AGENTS; HUMANS; VIDARABINE;

EID: 77955415920     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.06.004     Document Type: Article

References (78)

1. Snapper I., Marks D., Schwartz L., Hollander L. Hemolytic anemia secondary to Mesantoin. Ann Intern Med 1953, 39:619-623.
2. Harris J.W. Studies on the mechanism of a drug-induced hemolytic anemia. J Lab Clin Med 1956, 47:760-775.
3. Dausset J., Contu L. Drug-induced haemolysis. Ann Rev Med 1967, 18:55-70.
4. Worlledge S.M. Immune drug-induced haemolytic anaemias. Semin Hematol 1969, 6:181-200.
5. Petz L.D., Garratty G. Acquired immune hemolytic anemias 1980, Churchill Livingstone, New York.
6. Garratty G. Current viewpoints on mechanisms causing drug-induced immune hemolytic anemia and/or positive direct antiglobulin tests. Immunohematology 1989, 5:97-106.
7. Garratty G., Arndt P.A. An update on drug-induced immune hemolytic anemia. Immunohematology 2007, 23:105-119.
8. Hine L.K., Gertsman B.B., Wise R.P., Tsong Y. Mortality resulting from blood dyscrasias in the United States, 1984. Am J Med 1990, 88:151-153.
9. Andersohn F., Bronder E., Klimpel A., Garbe E. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin case-control surveillance study. Am J Hematol 2004, 77:316-318.
10. Kaufman D.W., Kelly J.P., Johannes C.B., Sandler A., Harmon D., Stolley P.D., et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993, 82:14-18.
11. van den Bemt P.M., Meyboom R.H., Egberts A.C. Drug-induced immune thrombocytopenia. Drug Saf 2004, 27:1243-1252.
12. Andrés E., Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008, 15:15-21.
13. Petz L.D., Garratty G. Immune hemolytic anemias 2004, Churchill Livingstone, Philadelphia. 2nd ed.
14. Klein N.P., Ray P., Carpenter D., Hansen J., Lewis E., Fireman B., et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010, 28:1062-1068.
15. Landsteiner K., van der Scheer J. On cross reactions of immune sera to azoproteins. II. Antigens with azocomponents containing two determinant groups. J Exp Med 1938, 67:709-723.
16. Eisen H.H., Orris L., Belman S. Elicitation of delayed allergic skin reactions with haptens; the dependence of elicitation on hapten combination with protein. J Exp Med 1952, 95:473-487.
17. Eisen H.N., Carsten M.E., Belman S. Studies of hypersensitivity to low molecular weight substances. III. The 2, 4-dinitrophenyl group as a determinant in the precipitin reaction. J Immunol 1954, 73:296-308.
18. Salama A., Mueller-Eckhardt C., Kissel K., Pralle H., Seeger W. Ex vivo antigen preparation for the serological detection of drug-dependent antibodies in immune haemolytic anaemias. Br J Haematol 1984, 58:525-531.
19. Salama A., Mueller-Eckhardt C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med 1985, 313:469-474.
20. Ackroyd J.F. The immunological basis of purpura due to drug hypersensitivity. Proc R Soc Med 1962, 55:30-36.
21. Miescher P.A., Miescher A. Die sedormid-anaphylaxie. Schweiz Med Wochenschr 1952, 82:1279-1282.
22. Miescher P.A., Gorstein F. Mechanisms of immunogenic platelet damage. Blood platelets 1961, 671. Churchill, London. S.A. Johnson, R.W. Monto, J.W. Rebuck, R.C. Horn (Eds.).
23. Miescher P.A., Pepper J.J. Drug-induced immunologic blood dyscrasias. Textbook of immunopathology 1976, 421-432. WB Saunders, Philadelphia. 2nd ed. P.A. Meischer, H.J. Müeller-Eberhard (Eds.).
24. Shulman N.R. Immunoreactions involving platelets. I. A steric and kinetic model for formation of complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complement by the complex. J Exp Med 1958, 107:665-690.
25. Shulman N.R., Rall J.E. Mechanism of blood cell destruction in individuals sensitized to foreign antigens. Trans Assoc Am Physicians 1963, 76:72-83.
26. Shulman N.R. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in autoimmunity. Ann Int Med 1964, 60:506-521.
27. Croft J.D., Swisher S.N., Gilliland B.C., Bakemeier R.F., Leddy J.P., Weed R.I. Coombs'-test positivity induced by drugs. Mechanisms of immunologic reactions and red cell destruction. Annals Int Med 1968, 68:176-187.
28. Garratty G., Petz L.D. Drug-induced immune hemolytic anemia. Am J Med 1975, 58:398-407.
29. Ley A.B., Harris J.P., Brinkley M., Liles B., Jack J.A., Cahan A. Circulating antibodies directed against penicillin. Science 1958, 127:1118-1119.
30. Garratty G. Immune cytopenia associated with antibiotics. Trans Med Rev 1993, VII:255-267.
31. Carstairs K.C., Breckenridge A., Dollery C.T., Worlledge S.M. Incidence of a positive direct Coombs test in patients on α-methyldopa. Lancet 1966, 2:133-135.
32. Worlledge S.M., Carstairs K.C., Dacie J.V. Autoimmune haemolytic anaemia associated with alpha-methyldopa therapy. Lancet 1966, 2:135-139.
33. Spath P., Garratty G., Petz L. Studies on the immune response to penicillin and cephalothin in humans. II. Immunohematologic reactions to cephalothin administration. J Immunol 1971, 107:860-869.
34. Ackroyd J.F. Immunological mechanisms in drug hypersensitivity. Clinical aspects of immunology 1975, 913. Blackwell Scientific, Oxford. 3rd ed. P.C.H. Gell, R.R.A. Coombs, P.J. Lachmann (Eds.).
35. Cronin AE. The immunology of allergic drug reactions. Doctoral thesis. Cambridge, MA: University of Cambridge, 1965.
36. Christie D.J., Mullen P.C., Aster R.H. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 1985, 75:310-314.
37. Smith M.E., Reid D.M., Jones C.E., Jordan J.V., Kautz C.A., Shulman N.R. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 1987, 79:912-917.
38. 2 domain to react. Blood 1985, 66(S):104a. abstr.
39. Habibi B. Drug induced red cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 1985, 61:139-143.
40. Mueller-Eckhardt C., Salama A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev 1990, IV:69-77.
41. Landsteiner K. The specificity of serological reactions 1947, 185. Harvard University Press, Cambridge, MA. Rev. ed.
42. Kitagawa M., Yagi Y., Pressman D. The heterogeneity of combining sites of antibodies as determined by specific immunoadsorbents. II. Comparison of elution patterns obtained with anti-p-azobenzoate antibodies by different kinds of immunoadsorbent and eluting hapten. J Immunol 1965, 95:455-465.
43. Allison A.C., Denman A.M., Barnes R.D. Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity. Lancet 1971, 298:135-140.
44. Gottlieb A.J., Wurzel H.A. Protein-quinone interaction: in vitro induction of indirect antiglobulin reactions with methyldopa. Blood 1974, 43:85-97.
45. LoBuglio A.F., Jandl J.H. The nature of the alphamethyldopa red-cell antibody. N Engl J Med 1967, 276:658-665.
46. Dameshek W. Alpha-methyldopa red-cell antibody: cross-reaction or forbidden clones. N Engl J Med 1967, 276:1382.
47. Kirtland H.H., Mohler D.N., Horwitz D.A. Methyldopa inhibition of suppressor-lymphocyte function. N Eng J Med 1980, 302:825-832.
48. Garratty G., Arndt P., Prince H.E., Shulman I.A. The effect of methyldopa and procainamide on suppressor cell activity in relation to red cell autoantibody production. Br J Haematol 1993, 84:310-315.
49. Garratty G., Arndt P.A. Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells. Br J Haematol 1998, 100:777-783.
50. Broadberry R.E., Farren T.W., Bevin S.V., Kohler J.A., Yates S., Skidmore I., et al. Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells. Transfus Med 2004, 14:53-57.
51. Arndt P.A., Leger R.M., Garratty G. Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells (letter). Vox Sang 2003, 85:53.
52. Arndt P., Garratty G., Isaak E., Bolger M., Lu Q. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorption. Transfusion 2009, 49:711-718.
53. Arndt P., Garratty G. Is severe immune hemolytic anemia, following a single dose of cefotetan, associated with the presence of "naturally-occurring" anti-cefotetan?. Transfusion 2001, 41:24S. abstr.
54. Arndt P.A., Leger R.M., Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion 1999, 39:1239-1246.
55. Anderson A.D., Nelson J.M., Rossiter S., Angulo F.J. Public health consequences of use of antimicrobial agents in food animals in the United States. Microb Drug Resist 2003, 9:373-379.
56. Shea K.M. Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics. Pediatrics 2004, 114:862-868.
57. Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf 2009, 8:73-79.
58. Garratty G. Drug-induced immune hemolytic anemia. Hematology. Am Soc Hematol Educ Program 2009, 73-79.
59. Davenport R.D., Judd W.J., Dake L.R. Persistence of cefotetan on red blood cells. Transfusion 2004, 44:849-852.
60. Doratota S., Recht M., Garratty G., Krupicka M., Thomas G.A., Boshkov L. Successful treatment of life-threatening ceftriaxone-induced hemolysis by plasmapheresis. Transfusion 2009, 49(S):13A. abstr.
61. Arndt P.A., Garratty G. Cross-reactivity of cefotetan and ceftiaxone antibodies, associated with hemolytic anemia, with other cephalosporins and penicillin. Am J Clin Pathol 2002, 118:256-262.
62. Viraraghavan R., Chakravarty A.G., Soreth J. Cefotetan-induced haemolytic anaemia. A review of 85 cases. Adv Drug React Toxicol Rev 2002, 21:101-107.
63. Garratty G., Leger R.M., Arndt P.A. Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol 1999, 181:103-104.
64. Arndt P.A. Practical aspects of investigating drug-induced immune hemolytic anemia due to cefotetan or ceftriaxone - a case study approach. Immunohematology 2002, 18:27-32.
65. Quillen K., Lane C., Hu E., Pelton S., Bateman S. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J 2008, 27:357-358.
66. Leger R.M., Arndt P.A., Garratty G. Serological studies of piperacillin antibodies. Transfusion 2008, 48:2429-2434.
67. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006, 33:230-239.
68. Di Raimondo F., Giustolisi R., Cacciola E., et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993, 11:63-68.
69. Myint H., Copplestone J.A., Orchard J., et al. Fludarabine-related autoimmune haemolyitc anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995, 91:341-344.
70. Gonzalez H., Leblond V., Azar N., et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998, 40:113-118.
71. Hamblin T.J., Orchard J.A., Myint H., Oscier D.G. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol 1998, 16:3209-3210.
72. Dearden C., Wade R., Else M., et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008, 111:1820-1826.
73. Weiss R.B., Freiman J., Kweder S.L., Diehl L.F., Byrd J.C. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998, 16:1885-1889.
74. Petz L.D. Immunohematologic problems associated with bone marrow transplantation. Transfus Med Rev 1987, 1:85-100.
75. Wong W., Merker J.D., Nguyen C., Berquist W., Jeng M., Viele M., et al. Cold agglutinin syndrome in pediatric liver transplant recipients. Pediatr Trnasplantation 2007, 11:931-936.
76. Kitamura T., Mizuta K., Kawarasaki H., Sugawara Y., Makuuchi M. Severe hemolytic anemia related to production of cold agglutinins following living donor liver transplantation: a case report. Transplant Proc 2003, 35:399-400.
77. DiGuiseppe J.A., Bastacky S.I., Shirey R.S., Silberman M.A., Hutchins G.M., Ness P.M. Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. Arch Pathol Lab Med 1996, 120:282-285.
78. Elimelakh M., Dayton V., Park K.S., Gruessner A.C., Sutherland D., Howe R.B., et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007, 92:1029-1036.